Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (June 2018)

Monday, August 20, 2018

Between January and June 2018, Russia imported 46.3 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 30.3% higher than that of the same period of 2017. In physical terms, the dynamics are -4.5%, which is true for the import of both pharmacopoeial and technical APIs. Since January 208, Russia has imported 5.4 tons of APIs.

The worst dynamics in physical terms belongs to amoxicillin (-39%), paracetamol (-35%), piracetam (-33%), and metronidazole (-33%.) However, despite the big import decrease, these APIs are among the leaders in the import volume.

There have also been changes in the import line. Between January and June 2018, Russia imported APIs of 496 INN names, while in 2017 it was 472. We can see 27 new pharmacopoeial APIs, with insulinum glarginum (imported by Sanofi) and insulinum detemirum (by Novo-Nordisk) leading in the import volume in monetary terms. The number of technical API names has decreased by 6, in particular, Russia stopped importing clozapine (Organica) and vancomycinum (Sintez and Miracle Pharma).

The number of importers of technical APIs has risen from 72 to 80, while that of pharmacopoeial APIs has risen from 425 to 433. Among the newcomers, Arene Lifesciences (India) is the leader, while importing only 4 APIs (for Pharmasyntez): pharmacopoeial abacavirum and technical atazanavirum, ritonavirum, and lopinavirum.

Read more about API import to Russia (May results) here: http://rncph.com/news/27_07_2018

Dynamics of import of pharmacopoeial and technical APIs to Russia (2015 – 2017, January – June 2018), bln RUB

Share: